The packet describes the condition as an inflammatory disease of the central nervous system. No genes are listed in the structured gene field, and inheritance patterns are not populated, so the packet does not certify a genetic basis or a mode of inheritance. The subtype list distinguishes forms by the presence or absence of anti-AQP4 and anti-MOG antibodies. Further causal mechanisms are not certified in this packet.

Diagnostic criteria, testing methods, and differential diagnoses are not certified in this packet. The only diagnostic-related information supplied is the subtype classification by anti-AQP4 and anti-MOG antibody status.

The packet lists three therapies with FDA approval records and an ACTIVE market status: ENSPRYNG (satralizumab), approved 2020-08-14; UPLIZNA (inebilizumab), approved 2020-06-11; and ULTOMIRIS (ravulizumab), approved 2018-12-21. All three are listed as BLA approvals through CDER, with orphan drug records indicating neuromyelitis optica or neuromyelitis optica spectrum disorder. Orphan designations, which are not approvals, are listed for cladribine, edralbrutinib, and ublituximab. Other treatment approaches are not certified in this packet.

Prognosis is not certified in this packet.

The packet records 65 clinical trials with active status on ClinicalTrials.gov. A trial title does not establish what an intervention does. Examples include NCT05199688, a Phase 3 study of satralizumab in pediatric patients with aquaporin-4 antibody positive disease, sponsored by Hoffmann-La Roche and recruiting, and NCT07557420, a Phase 3 study of ravulizumab in Chinese adults, sponsored by Alexion Pharmaceuticals and recruiting. The Guthy-Jackson Charitable Foundation is listed as a patient organization with a registry, and two assistance programs (Good Days and the National Organization for Rare Disorders) are listed as accepting enrollment.